Table 3.
Tumour and cancer stage–specific disease-free survival and overall survival rates
| Stage* | Group; no. (%) | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Disease-free survival | Overall survival | |||||
|
|
|
|||||
| Lobectomy, n = 223 | Wedge resection, n = 43 | p value† | Lobectomy, n = 223 | Wedge resection, n = 42 | p value† | |
| Tumour stage | 0.043 | 0.081 | ||||
|
| ||||||
| T1a | 67 (30.0) | 18 (41.9) | 71 (30.5) | 22 (52.4) | ||
|
| ||||||
| T1b | 58 (26.0) | 9 (20.9) | 57 (24.5) | 9 (21.4) | ||
|
| ||||||
| T2a | 67 (30.0) | 11 (25.6) | 73 (31.3) | 8 (19.0) | ||
|
| ||||||
| T2b | 15 (6.8) | 1 (2.3) | 12 (5.1) | 1 (2.4) | ||
|
| ||||||
| T3 | 14 (6.3) | 1 (2.3) | 18 (7.7) | 1 (2.4) | ||
|
| ||||||
| T4 | 2 (0.9) | 3 (7.0) | 2 (0.9) | 1 (2.4) | ||
|
| ||||||
| Cancer stage | 0.008 | 0.088 | ||||
|
| ||||||
| IA | 110 (49.3) | 107 (45.9) | 23 (53.5) | 26 (61.9) | ||
|
| ||||||
| IB | 43 (19.2) | 45 (19.3) | 9 (20.9) | 7 (16.6) | ||
|
| ||||||
| IIA | 39 (17.5) | 46 (19.8) | 1 (2.3) | 2 (4.8) | ||
|
| ||||||
| IIB | 19 (8.5) | 22 (9.5) | 2 (4.7) | 2 (4.8) | ||
|
| ||||||
| IIIA | 10 (4.5) | 11 (4.7) | 8 (18.6) | 5 (11.9) | ||
|
| ||||||
| IIIB | 1 (0.5) | 1 (0.4) | 0 | 0 | ||
|
| ||||||
| IV | 1 (0.5) | 1 (0.4) | 0 | 0 | ||
AJCC = American Joint Committee on Cancer.
*
Tumour stage and cancer stage are based on the AJCC, seventh edition.
†
p values are based on the Pearson χ2 test.